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Abstract
Instruction: Longer atrial fibrillation (AF) durations have higher recurrence rates
after rhythm control. However, there is limited data on the effect of the AF duration
on recurrence after atrial fibrillation catheter ablation (AFCA). In the present study,
we investigated the rhythm outcome of AFCA according to the AF duration based on
the first electrocardiogram (ECG) diagnosis.
Methods and Results: We included 1005 patients with AF (75% male, 59 ± 11 years
old) who underwent AFCA and whose first ECG diagnosis time point was evident. The
clinical characteristics and rhythm outcomes were compared based on the AF duration
(≤3 years, n = 537; >3 years, n = 468) and AF burden (paroxysmal atrial fibrillation [PAF],
n = 387; persistent atrial fibrillation [PeAF], n = 618). Longer AF durations were
associated with older age (P = .020), larger left atrial size (P = .009) and a higher number
of patients with hypertension (P < .001) or PeAF (P < .001). During 24 ± 22 months of
follow‐up, the postablation clinical recurrence rate was higher in patients with a longer
AF duration (logrank P = .002). The AF recurrence rate was significantly higher in PeAF
patients with an AF duration >3 years (logrank P = 0.009), but not in subjects with PAF
(logrank P = .939). In a multivariate Cox regression analysis, a longer AF duration was
significantly associated with a higher clinical recurrence rate after AFCA in PeAF
patients (adjusted hazard ratio, 1.06; range, 1.03‐0.10; P = 0.001), but not PAF.
Conclusion: Although longer AF duration was associated with higher clinical
recurrence rates after AFCA, the rate was significant in patients with PeAF lasting
>3 years, but not in PAF patients.
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1 | INTRODUCTION
Atrial fibrillation (AF) is a chronic degenerative disease with a 1.5%
prevalence of the total population and continuously increasing in the
elderly population.1 AF is also a progressive disease with annual
progression rates of 7% to 15%,2,3 and more than 50% of paroxysmal
atrial fibrillation (PAF) will progress to persistent atrial fibrillation
(PeAF) within 10 years.4 AF progresses more rapidly to more
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persistent forms in PeAF than in PAF patients,5 and in patients with a
higher number of cardiovascular risk factors.6 The aggressive rhythm
control slows the AF progression, and the AF progression rate is
3.3‐fold lower in the rhythm‐control group than the rate control
group.3,6 Catheter ablation of AF is an effective rhythm control
strategy that reduces the AF burden, heart failure mortality,7 risks of
a stroke,8 and risk of cognitive dysfunction.9
The AF duration has been considered an important prognostic
factor for the rhythm outcome after a maze procedure10 or AF
ablation.11 However, AF is less consistent with symptoms and
asymptomatic subclinical AF is common. Reportedly, over 40% of
patients did not complain of any significant symptoms under an
appropriate rate control.12 Therefore, determining the exact AF
duration based on the symptoms is difficult. However, we measured
the time period from the first electrocardiogram (ECG) diagnosis
of AF to the de novo atrial fibrillation catheter ablation (AFCA) in
our AF ablation study population. In addition, we monitored the
postablation AF recurrence by a consistent long‐term rhythm
monitoring protocol according to the 2012 HRS/EHRA/ECAS Expert
consensus statement guidelines.13,14 In the present study, we tested
the hypothesis whether the documented ECG‐based AF duration
was closely associated with a high recurrence rate after radio-
frequency AFCA.
2 | METHODS
2.1 | Study population
The study protocol adhered to the Declaration of Helsinki and was
approved by the Institutional Review Board of the Yonsei University
Health System. All patients provided written informed consent for
inclusion in the Yonsei AF Ablation Registry Database (registered at
clinicaltrials.gov as NCT02138695). From March 2009 to September
2017, 1005 patients who underwent AFCA for AF and whose first
ECG diagnosis time point was evident were analyzed (75% male,
59 ± 11 years of age, 39% PAF). AF onset was defined as the index
ECG showing AF. AF that terminates spontaneously or with
intervention within 7 days of onset was classified as PAF.15 We
analyzed the sensitivity and specificity for predicting clinical
recurrences of AF after AFCA on the basis of the different cut‐off
ranges of the AF duration (Figure 1 and Table S1). As a result of the
analysis, the 3‐year cut‐off value represented the best dichotomy
among a number of tested cut‐off values. Therefore, we compared
the patients with an AF duration of less than 3 years and those with
that longer than 3 years based on a preliminary adjusted hazard ratio
(HR) analysis. The clinical characteristics and rhythm outcomes were
compared based on the AF duration (≤3 years, n = 537; >3 years,
n = 468) and AF burden (PAF, n = 387; PeAF, n = 618). Exclusion
criteria were as follows: (a) valvular AF, (b) structural heart disease
other than left ventricular hypertrophy, (c) left atrial (LA) diameter
≥60mm, and (d) a history of a previous AF ablation or cardiac
surgery. All antiarrhythmic drugs (AADs) were discontinued for a
minimum period of five half‐lives before the procedure. Antic-
oagulation therapy was maintained before the catheter ablation. The
anatomy of the LA and the pulmonary veins (PVs) in all patients was
imaged using three‐dimensional (3D) spiral computed tomography
(CT) scans (64 Channel, LightSpeed Volume CT, Philips, Brilliance 63,
Amsterdam, Netherlands).
2.2 | Electroanatomical mapping and
echocardiographic evaluation
Intracardiac electrograms were recorded using the Prucka
CardioLab Electrophysiology System (General Electric Medical
Systems, Inc, Milwaukee, WI), and AFCA was performed in all
patients using 3D electroanatomical mapping (NavX, St Jude Medical,
Inc, Minnetonka, MN) merged with 3D spiral CT. Transseptal
punctures were made and multiview pulmonary venograms were
obtained. Systemic anticoagulation was performed with intravenous
heparin to maintain an activated clotting time of 350 to 400 seconds
during the procedure. For electroanatomical mapping, the 3D
geometry of both the LA and the PVs was generated using the NavX
system and then merged with 3D spiral CT images. LA electrogram
voltage maps were generated during high right atrial pacing at
500ms to prevent rate‐dependent activation changes after main-
taining sinus rhythm by circumferential pulmonary vein isolation
(CPVI) with or without cardioversion. If frequently recurring AF
persisted after three attempts at cardioversion, no further efforts
were made to generate an LA voltage map. The peak‐to‐peak
amplitude of the contact bipolar electrograms was obtained from
350 to 500 points on the LA endocardium and the mean LA




















F IGURE 1 The adjusted hazard ratio of atrial fibrillation (AF)
duration for AF recurrence. Adjusted for age, sex, body mass index,
paroxysmal atrial fibrillation, heart failure, hypertension, diabetes,
stroke or transient ischemic attack, left atrium diameter, left
ventricle ejection fraction
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All patients underwent transthoracic echocardiography (Sonos
5500; Philips Medical Systems, Andover, MA; Vivid 7, GE Vingmed
Ultrasound, Horten, Norway) before the AFCA. Transesophageal
echocardiography or intracardiac echocardiography was performed
to exclude any intracardiac thrombi. The emptying velocity of the LA
appendage was measured in all patients.
2.3 | Atrial fibrillation catheter ablation
The details of the AFCA technique and strategy were described in
our previous study.16 Briefly, for the CPVI ablation, continuous
circumferential lesions were created at the level of the LA antrum
encircling the right and left PVs guided by the NavX system using an
open‐irrigated, 3.5‐mm tip deflectable catheter at 30 to 35W and
45°C (ThermoCool, Johnson & Johnson, Inc, Diamond Bar, CA; Cool
Flex, St Jude Medical, Inc). A CPVI and cavotricuspid isthmus ablation
were performed in all patients. The endpoints of both the CPVI and
cavotricuspid isthmus block were defined based on bidirectional
pacing. For patients with persistent AF, a roofline, posterior‐inferior
line, and anterior line were added as a standard lesion set. At the
operator’s discretion, additional ablation of the superior vena cava,
non‐PV foci, or complex fractionated electrograms was conducted.
The procedure ended when no immediate recurrence of AF was
observed within 10minutes after cardioversion with an isoproterenol
infusion (5‐10 μg/min). Non‐PV foci under an isoproterenol infusion
were also ablated.
2.4 | Postablation follow‐up
The patients without antiarrhythmic medications were discharged
after the procedure unless early recurrence of AF/AT or symptomatic
frequent atrial premature beats were evident. Patients visited the
outpatient clinic regularly at 1, 3, 6, and 12 months and then every
6 months or whenever symptoms occurred after the AFCA. All
patients underwent ECG at each visit and 24‐hour Holter recordings
at 3 and 6 months and every 6 months thereafter following the
2012 HRS/EHRA/ECAS Expert Consensus Statement guidelines.13
Holter monitoring or event monitor recordings were obtained
when patients reported symptoms of palpitation suggestive of
arrhythmia recurrence. AF recurrence was defined as any episode
of AF or AT of at least 30 seconds in duration. Any ECG
documentation of an AF recurrence within a 3‐month blanking
period was diagnosed as an early recurrence and an AF recurrence
more than 3 months after the procedure was diagnosed as a clinical
recurrence.
2.5 | Statistical analyses
Continuous variables were summarized as the mean ± standard
deviation and compared using a Student t test and analysis of
variance. Categorical variables were summarized as a percentage of
the group total and compared using the χ2 test or Fisher’s exact
test. To predict clinical recurrence of AF after AFCA on the basis
of different cut‐off ranges of AF duration, receiver operating
characteristic curves were constructed. A multivariate Cox regres-
sion analysis was used to identify the predictors of clinical
recurrence. Variables with a P value less than .05 based on univariate
analysis were selected for the multivariate analysis. In addition, if a
significant correlation between the selected variables (R > .5) was
observed, only one variable was used to avoid multicollinearity in
the multivariate regression analysis. A Kaplan‐Meier analysis with
a logrank test was used to calculate the AF recurrence‐free
survival over time and to compare the recurrence rates across the
groups. A P value less than .05 was considered statistically significant.
The statistical analyses were performed using SPSS (version 25.0;
Statistical Package for Social Sciences, Chicago, IL) software for
Windows.
3 | RESULTS
3.1 | Baseline characteristics
The baseline clinical characteristics of the study population are
shown in Table 1. We compared the patient with AF duration
less than 3 years and those with longer than 3 years based on
preliminary adjusted HR analysis (Figure 1). The sex distribution did
not statistically significantly differ between the two groups. A longer
AF duration was associated with older age (P = .020), a higher
number of patients with hypertension (P < .001) and PeAF (P < .001).
The LA diameter on echocardiography also increased as the AF
duration increased (P = .009), while the endocardial voltage of the LA
decreased as the AF duration increased (P < .001). Other comorbid-
ities including the CHA2DS2‐VASc score and baseline echocardio-
graphic and CT parameters did not significantly differ between the
groups.
3.2 | Procedural results and clinical outcome after
catheter ablation of AF
The procedural results and clinical outcomes are summarized in
Table 2. The total procedure time (P = .152) and ablation time
(P = .548) did not statistically differ between the two groups,
however, the AAD utility rates at discharge were higher in the
patients with a longer preprocedural AF duration (14.2% vs 21.0%;
P = .005). During 24 ± 22 months of follow‐up after the AF ablation,
the early recurrence rate (27.6% vs 39.0%; P < .001) and clinical
recurrence rate (24.9% vs 36.9%; P < .001) were significantly higher
in the longer AF duration group (Table 2). The Kaplan‐Meier analysis
also showed a significantly higher clinical recurrence of AF in patients
with a longer preprocedural AF duration (Figure 2, logrank P = .002).
In the subgroup analysis based on the AF type, the clinical recurrence
YU ET AL. | 459
rate did not significantly differ among the patients with PAF
(Figure 3A, logrank P = .939). However, in the PeAF group, the
clinical recurrence rate was significantly higher in patients with a
longer AF duration (Figure 3B, logrank P = .009).
3.3 | AF duration as a predictor of a clinical
recurrence of AF after catheter ablation
Univariate and multivariate Cox regression analyses were per-
formed to identify the predictors of a clinical recurrence of AF
after catheter ablation (Table 3). In patients with PAF, a female sex
(HR, 0.470; 95% confidence interval [CI], 0.233‐0.948; P = .035), a
lower body surface area (HR, 0.131; 95% CI, 0.019‐0.913;
P = .040), and a lower LA voltage (HR, 0.386; 95% CI, 0.173‐
0.862; P = .020) were associated with a higher clinical recurrence
of AF after catheter ablation based on the univariate analysis. The
AF duration was not significantly associated with a clinical
recurrence after AFCA in patients with PAF. On the other hands,
in patients with PeAF, a larger LA diameter (HR, 1.042; 95% CI,
1.012‐1.073; P = .005), a lower LA voltage (HR, 0.331; 95% CI,
0.213‐0.514; P < .001), and a longer AF duration (HR, 1.065; 95%
CI, 1.033‐1.099; P < .001) were associated with a higher clinical
recurrence of AF after catheter ablation based on the univariate
TABLE 1 Baseline characteristics of the patients
AF duration ≤3 y (n = 537) AF duration >3 y (n = 468) P value
Age, y 58.2 ± 11.2 59.7 ± 10.0 .020*
Male sex, n (%) 391 (72.8) 363 (77.6) .083
Paroxysmal AF, n (%) 238 (44.3) 149 (31.8) <.001*
BSA, m2 1.81 ± 0.19 1.82 ± 0.18 .795
BMI, kg/m2 25.1 ± 3.1 25.0 ± 3.4 .529
Comorbidities
Heart failure, n (%) 75 (14.0) 66 (14.1) .951
Hypertension, n (%) 211 (39.3) 237 (50.6) <.001*
Diabetes mellitus, n (%) 88 (16.4) 73 (15.6) .745
Stroke or TIA, n (%) 84 (15.6) 64 (13.7) .380
Vascular Disease, n (%) 74 (13.8) 69 (14.7) .663
CHA2DS2‐VASc score 1.8 ± 1.6 1.8 ± 1.5 .567
Echocardiography
LA diameter, mm 42.1 ± 6.1 43.2 ± 6.3 .009*
LA volume index, mL/m2 39.2 ± 13.3 40.7 ± 13.0 .077
LV ejection fraction, % 62.5 ± 8.3 61.9 ± 9.3 .271
E/Em 10.3 ± 4.6 10.4 ± 4.0 .865
LVEDD, mm 49.9 ± 4.8 50.2 ± 4.6 .264
LAA emptying velocity, cm/s 44.8 ± 21.7 43.1 ± 20.6 .314
CT/NavX (n = 976)
LA volume/BSA, mL/m2 87.7 ± 24.1 91.3 ± 26.0 .025*
Pericardial fat volume, cm3 128.7 ± 58.9 128.9 ± 56.0 .956
LA endocardial voltage, mV 1.28 ± 0.64 1.04 ± 0.55 <.001*
Abbreviations: AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; BSA, body surface area; CT, computed tomography; E/Em, early mitral
inflow velocity over the early diastolic mitral annular velocity; LA, left atrium; LAA, left atrial appendage; LV, left ventricle; LVEDD, left ventricular end‐
diastolic dimension; TIA, transient ischemic attack.
*P < .05.
TABLE 2 Procedural results and clinical outcomes
AF duration ≤3 y (n = 537) AF duration >3 y (n = 468) P value
Procedure time, min 195.2 ± 48.4 200.0 ± 56.5 .152
Ablation time, s 5275 ± 1656 5204 ± 2009 .548
AAD at discharge, n (%) 76 (14.2) 98 (21.0) .005*
Follow‐up duration, mo 23.0 ± 20.9 24.2 ± 22.9 .363
Early recurrence, n (%) 141 (27.6) 174 (39.0) <.001*
Clinical recurrence, n (%) 127 (24.9) 164 (36.9) <.001*
Abbreviations: AAD, antiarrhythmic drug; AF, atrial fibrillation.
*P < .05.
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analysis. In the multivariate Cox regression analysis, a larger LA
diameter (adjusted HR, 1.058; 95% CI, 1.015‐1.102; P = .007), a
lower LA voltage (adjusted HR, 0.365; 95% CI, 0.227‐0.586;
P < .001) and a longer AF duration (adjusted HR, 1.064; 95% CI,
1.025‐1.104; P = .001) was significantly associated with a higher
clinical recurrence of AF in patients with PeAF.
Given the higher comorbidity of patients with PeAF, we
additionally performed a propensity score match analysis between
patients with PeAF and PAF in terms of age, sex, and the
comorbidities that make up the CHA2DS2‐VASc score. After a
propensity score matching, the matched population showed
results consistent with the overall population in terms of the AF
burden (paroxysmal or persistent) and AF duration (Table S2 and
Figure 4).
4 | DISCUSSION
4.1 | Main findings
In the present study, the time period from the first ECG diagnosis
of AF to the AFCA and clinical recurrence was measured using
guideline‐based rhythm monitoring. The longer duration of AF was
associated with a higher clinical recurrence rate after catheter
ablation but was only significant in the patients with PeAF lasting
more than 3 years. An AF duration‐dependent difference in the
clinical recurrence rate was not observed in the patients with PAF.
4.2 | AF progression and catheter ablation
AF is a chronic degenerative rhythm disorder with continuous
progression associated with aging, LA enlargement, and heart
failure.17 AF progression is more significant and accelerated in
patients with associated hypertension, valvular disease, chronic
lung disease, and a previous ischemic stroke.18,19 AFCA is an
effective rhythm control strategy to reduce the AF burden,
however, the evolution of the abnormal atrial substrate progresses
despite a successful ablation procedure and likewise the aging
process.20 Furthermore, the development and advances in the
catheter ablation technology, as well as the accumulated experi-
ence, have not been translated into a significant procedural
success.21 Park et al14 found that extra‐PV ablation and 1‐year
recurrence rates in the AF ablation study cohort have been
decreasing in part due to the improved catheter technology in the
past 9 years. However, patients with a first recurrence continue to
appear consistently even after 5 years from successful catheter
ablation. Obesity,22 metabolic syndromes,23 and obstructive sleep
apnea24 are associated with a high probability of an AF recurrence
after catheter ablation. Therefore, strategies aiming at a reduction
in AF development or progression, such as lifestyle and risk factor
management, are necessary to improve the therapeutic outcome of
AFCA.25–28
4.3 | Why persistent AF ablation is more likely
affected by the AF duration?
In the present study, a longer AF duration, especially longer than 3
years, was associated with a higher clinical recurrence of atrial
arrhythmias after catheter ablation in patients with PeAF, but not in
AF duration ≤ 3 years 

































F IGURE 2 Kaplan‐Meier analysis of the AF recurrence‐free
survival after catheter ablation in the total study population. AF,
atrial fibrillation
 Paroxysmal AF Persistent AF






























































AF duration ≤ 3 years
AF duration > 3 years
(A) (B)
F IGURE 3 Kaplan‐Meier analysis of the AF recurrence‐free survival after catheter ablation in patients with paroxysmal AF (A) and
persistent AF (B). AF, atrial fibrillation
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subjects with PAF. There are several potential explanations for this
outcome. First, PAF or PeAF without significant progression can be
mostly manageable by a circumferential PV isolation.21 However,
PeAF with significant remodeling is generally accompanied by
multiple non‐PV triggers29 and appropriate treatment is limited to
the current ablation technology. Second, the PeAF category
includes an excessively broad spectrum of AF progression and
remodeling compared with PAF. The definition of PeAF in the
current guidelines30 is based only on a 1‐week sustained duration of
AF and does not reflect the degree of atrial remodeling. Some of the
early PeAF cases regressed to PAF after AAD therapy, however,
several progressed to permanent AF. Third, the presence of
subclinical AF may have delayed the ECG‐based diagnosis of AF.12
Therefore, in the case of asymptomatic or minimally symptomatic
AF, the ECG‐based AF duration may be underestimated compared
with the actual AF duration in patients with PeAF lasting more than
3 years.
4.4 | Clinical implications
The recommended AF rhythm control in the current guidelines is
intended for patients with symptomatic AF rather than ECG‐based
AF.30,31 However, AF progression to PeAF or permanent AF is
accompanied by high cardiovascular risk and long‐term mortality.32,33
In addition, metabolic syndrome, which is associated with AF
progression, increases the nonthromboembolic adverse cardiac out-
comes in patients with AF.34 Therefore, a symptom‐based AF ablation
can be justified in the PAF state; however, when progressing to PeAF,
rhythm control should be considered even in patients with minimal
symptoms to prevent the progression to permanent AF. On the basis
of the results from the current analysis, a favorable outcome of AFCA
can be expected for patients with PAF regardless of the AF duration,
or those with PeAF found within 3 years. When performing catheter
ablation for patients with PeAF that has lasted more than 3 years, a
higher recurrence rate should be carefully considered.
TABLE 3 Predictors for a clinical recurrence after catheter ablation of AF
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Paroxysmal AF (n = 387)
Age, y 0.989 (0.959‐1.021) .499 0.970 (0.935‐1.008) .117
Male sex 0.470 (0.233‐0.948) .035* 0.537 (0.172‐1.677) .284
BSA, m2 0.131 (0.019‐0.913) .040* 0.402 (0.015‐10.490) .584
BMI, kg/m2 0.940 (0.836‐1.056) .295
Heart failure 0.722 (0.211‐2.475) .605
Hypertension 1.294 (0.646‐2.593) .467
Diabetes mellitus 0.696 (0.236‐2.057) .513
Stroke or TIA 2.106 (0.929‐4.775) .075
Vascular disease 1.298 (0.510‐3.300) .584
LA diameter, mm 0.958 (0.899‐1.021) .187
LAVI, mL/m2 1.003 (0.975‐1.032) .820
LV ejection fraction (%) 1.014 (0.970‐1.060) .544
E/Em 0.939 (0.845‐1.043) .238
LA voltage, mV 0.386 (0.173‐0.862) .020* 0.455 (0.191‐1.086) .076
AF duration, y 0.923 (0.815‐1.046) .208 0.983 (0.870‐1.110) .781
Persistent AF (n = 618)
Age, y 0.996 (0.981‐1.011) .588 0.990 (0.971‐1.010) .336
Male sex 1.063 (0.721‐1.569) .757 1.047 (0.626‐1.752) .860
BSA, m2 1.364 (0.569‐3.267) .486
BMI, kg/m2 1.008 (0.961‐1.058) .737
Heart failure 0.519 (0.325‐0.829) .006* 0.429 (0.230‐0.800) .008*
Hypertension 1.029 (0.744‐1.423) .863
Diabetes mellitus 0.729 (0.469‐1.133) .160
Stroke or TIA 0.788 (0.497‐1.250) .312
Vascular disease 1.034 (0.658‐1.625) .886
LA diameter, mm 1.042 (1.012‐1.073) .005* 1.058 (1.015‐1.102) .007*
LAVI, mL/m2 1.008 (0.995‐1.021) .234
LV ejection fraction (%) 1.009 (0.991‐1.029) .322
E/Em 0.976 (0.939‐1.014) .207
LA voltage, mV 0.331 (0.213‐0.514) <.001* 0.365 (0.227‐0.586) <.001*
AF duration, y 1.065 (1.033‐1.099) <.001* 1.064 (1.025‐1.104) .001*
Abbreviations: AF, atrial fibrillation; BMI, body mass index; BSA, body surface area; CI, confidence interval; E/Em, early mitral inflow velocity over the
early diastolic mitral annular velocity; HR, hazard ratio; LA, left atrium; LAVI, left atrial volume index; LV, left ventricle; TIA, transient ischemic attack.
*P < .05.
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4.5 | Limitations
The present study had several limitations. First, although we
attempted to define the duration of AF in patients with a clear
time point for the first ECG diagnosis, the possibility of a
discrepancy between the ECG‐based AF duration and actual AF
duration remains. Especially in patients with PAF, the duration of
AF was more difficult to determine and thus the relationship
between an AF recurrence and the AF duration in those patients
was less clear. Second, contrary to the continuous rhythm
monitoring using an implantable loop recorder, the current
guideline‐based consistent rhythm monitoring schedule could not
detect all the subclinical AF episodes. Third, this was an observa-
tional study from a single‐center cohort that included a highly
selected group of patients referred for AFCA. Despite this
limitation, a realistic and consistent rhythm monitoring method
was applied for all patients included in the AF ablation study cohort
based on real‐world practice.
5 | CONCLUSION
A longer duration of AF was associated with a higher clinical
recurrence rate after catheter ablation; however, a significance was
only observed in patients with PeAF of more than 3 years. An AF
duration‐dependent difference in the clinical recurrence rate was not
observed in patients with PAF.
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